4//SEC Filing
Mandelia Ashish 4
Accession 0001104659-25-004597
CIK 0001442836other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 7:27 PM ET
Size
18.3 KB
Accession
0001104659-25-004597
Insider Transaction Report
Form 4
Mandelia Ashish
VP, Chief Accounting Officer
Transactions
- Exercise/Conversion
Restricted Stock Unit
2025-01-15−4,166→ 12,501 total→ Common Stock (4,166 underlying) - Award
Restricted Stock Unit
2025-01-15+16,667→ 16,667 total→ Common Stock (16,667 underlying) - Exercise/Conversion
Common Stock
2025-01-15+4,519→ 56,907 total - Exercise/Conversion
Common Stock
2025-01-15+4,166→ 61,073 total - Sale
Common Stock
2025-01-16$0.58/sh−3,554$2,061→ 57,519 total - Exercise/Conversion
Restricted Stock Unit
2025-01-15−4,519→ 0 total→ Common Stock (4,519 underlying) - Award
Stock Option (Right to Buy)
2025-01-15+75,000→ 75,000 totalExercise: $0.64Exp: 2035-01-14→ Common Stock (75,000 underlying)
Footnotes (9)
- [F1]Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 15, 2021.
- [F2]Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2024.
- [F3]Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- [F6]Fully vested as of January 15, 2025.
- [F7]25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years.
- [F8]The option shall vest in equal quarterly installments over four years from the date of grant.
- [F9]The RSUs shall vest in equal annual installments over four years from the date of grant.
Documents
Issuer
Mersana Therapeutics, Inc.
CIK 0001442836
Entity typeother
Related Parties
1- filerCIK 0001782805
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 7:27 PM ET
- Size
- 18.3 KB